CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Neuroscience Startups (947)
Annovis Bio (NYSE: ANVS) is a clinical-stage, drug platform company addressing chronic and acute neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). Annovis' approach is to d...Show all
Company (IPO / Went public)
Phone: 610-727-3913
1055 Westlakes Drive
Suite 300
Berwyn, 19312
Pennsylvania, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Annovis Bio | $11.9M | Jan 29, 2020 |
| Intarcia Therapeutics | $1712.2M | Mar 12, 2019 |
| Hyperion Therapeutics | $206.6M | Mar 30, 2015 |
| See all 19 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Pantograph damage and wear monitoring system | Aug 06, 2008 | Jun 23, 2015 | Patent |
| Estimation of wheel rail interaction forces | Jun 08, 2006 | Dec 14, 2010 | Patent |
| (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Mar 06, 2017 | Application | |
| Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3 b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Jun 30, 2015 | Application |
